Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
Open Access
- 2 July 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (7), 787-796
- https://doi.org/10.1080/17512433.2020.1787832
Abstract
Previous reviews of PCSK9 inhibitor trials are limited by a focus on composite cardiovascular outcomes. ClinicalTrials.gov provides trial results for individual clinical outcomes. Aim of this systematic review was to assess the effect of PCSK9 inhibitors on the risk of myocardial infarction, stroke/TIA, heart failure, diabetes mellitus, neurocognitive events, all-cause serious adverse events (SAE) and all-cause deaths as registered on ClinicalTrials.gov. PubMed, regulatory reports, ClinicalTrials.gov, and company websites were used to search studies. Randomized trials comparing PCSK9-inhibitor with placebo in participants with hypercholesterolemia were eligible. Study characteristics, risk of bias, and numbers of participants with the outcomes of interest were collected. We identified 33 lipid-lowering and 4 clinical outcomes trials with results on ClinicalTrials.gov (n=16,958 and n=73,836 respectively). Risk of bias was generally high. PCSK9 inhibitors did not affect the risk of any of the investigated outcomes in either type of trial. However, in clinical outcomes studies, alirocumab decreased the risk of all-cause SAE (OR 0.92; 95% CI 0.86-0.98), and evolocumab increased the risk of mortality (OR 1.12; 95% CI 1.00-1.26; p<.05). Our meta-analysis of clinical events registered on ClinicalTrials.gov did not show that PCSK9 inhibitors improve cardiovascular health. Evolocumab increased the risk of all-cause mortality.Keywords
This publication has 65 references indexed in Scilit:
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Atorvastatin with or without an Antibody to PCSK9 in Primary HypercholesterolemiaThe New England Journal of Medicine, 2012
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial HypercholesterolemiaCirculation, 2012
- Third Universal Definition of Myocardial InfarctionCVD Prevention and Control, 2012
- Challenges in Coding Adverse Events in Clinical Trials: A Systematic ReviewPLOS ONE, 2012
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJournal of Invasive Cardiology, 2012
- Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic reviewBMJ, 2010
- Reporting “Basic Results” in ClinicalTrials.govSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary InterventionJournal of Invasive Cardiology, 2008
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004